Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)
Sponsor: Alkermes, Inc.
This PHASE3 trial investigates Bipolar I Disorder and Schizophrenia and is currently actively recruiting participants. Alkermes, Inc. leads this study, which shows 20 recorded versions since 2022 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
20 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Nov 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Aug 2025 [monthly]
Recruiting PHASE3
▶ Show 15 earlier versions
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Nov 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE3
-
Oct 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Sep 2022 — Oct 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .